Analysts Offer Insights on Healthcare Companies: MaxCyte (MXCT) and Incyte (INCY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on MaxCyte (MXCT) and Incyte (INCY).
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
MaxCyte (MXCT)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on MaxCyte today. The company’s shares closed last Thursday at $1.12.
According to TipRanks.com, Hewitt has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
MaxCyte has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
Incyte (INCY)
In a report released today, Matt Phipps from William Blair maintained a Hold rating on Incyte. The company’s shares closed last Thursday at $108.78.
According to TipRanks.com, Phipps is a 2-star analyst with an average return of
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $110.38, implying a 4.2% upside from current levels. In a report issued on June 8, Oppenheimer also maintained a Hold rating on the stock with a $107.00 price target.
Read More on MXCT:
